Nanosyrinx

Activities: Digital

Trending Articles

  1. Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    The last word on mRNA analysis: trends, challenges and what’s next Advances in LC–MS, automation and data integration are transforming mRNA analysis from niche experimentation into a cornerstone of regulated CMC workflows, writes Matt Boag,...
  3. Clarivate releases Drugs to Watch 2026 report The report features 11 breakthrough therapies shaping obesity, women's health, rare disease care and oncology innovation from companies such as Eli Lilly and GSK
  4. Eli Lilly pays $55m for obesity drug research collab with Nimbus Therapeutics The pair have entered into a multi-year research collaboration to develop a novel oral treatment for obesity and other metabolic diseases
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    From pilots to production: what 2026 could mean for pharma This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the...

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO

Appointment supports NanoSyrinx’s transition from platform development to clinical-stage intracellular medicines
Drug Delivery

Nanosyrinx appoints Edwin Moses as its Chairperson

With more than 30 years of executive-level experience, Edwin will aim to maximise the value of the company's nanosyringe platform
Subscribe now